Theralase Presents X-Ray Activation at International World Congress
Toronto, Ontario – June 14, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on X-ray activation of PDCs was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal.
The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two years and is quickly becoming known as the premier forum to communicate outstanding advances in the clinical and research aspects of PDT and PD.
Pavel Kaspler, Ph.D, Theralase presented, “X-ray and Photon Mediated in-vitro and in-vivo Activity of Ruthenium(II)-Based Compounds.”
Dr. Kaspler presented how the Theralase patented PDC, TLD-1433, has demonstrated pre-clinically that it has a(n):
- Small mass of approximately 1kiloDalton (small enough in molecular weight to cross a cell’s membrane barrier)
- High Reactive Oxygen Species (“ROS”) quantum yield (close to unity for 1O2) (the higher the conversion of delivered photons of light to production of ROS, the higher the PDC’s efficacy in the destruction of cellular targets)
- High PDT efficacy (destroying cancer cells while leaving healthy tissue intact)
- Ability to absorb energy in the X-ray range (X-rays are able to pass directly through human tissue allowing significant depth of penetration)
Dr. Kaspler presented how the TLD-1433 injected intratumorally in a Balb/C mouse animal model has a greater than 90% cell kill in human GlioBlastoma Multiforme (“GBM”) cancer treated pre-clinically with a low dose of X-ray (1 Gy, 75 keV) and then activated by Near Infrared (“NIR”) laser light (808 nm, 200 J/cm2), four hours after injection.
Dr. Kaspler stated that, “X-ray followed by NIR laser light activation of TLD-1433 is a new and unexpected discovery by the members of our research team under the leadership of Dr. Arkady Mandel and Dr. Lothar Lilge. This discovery has far reaching implications, including: targeting cancers that are difficult, if not impossible to reach with conventional laser light sources, such as GBM brain tumours or deep tissue related cancers.”
Dr. Kaspler concluded in his presentation that TLD-1433 is:
- Stable under X-ray activation and remains able to produce ROS via subsequent NIR laser light activation
- Able to be activated by X-ray eliciting a PDT-like cell kill
- Able to be dually activated (X-ray followed by NIR laser) delivering a cell kill greater than the two wavelengths applied separately
- Able to destroy cancer cells predominantly via necrosis at 24 hours post treatment.
- Able to deliver noticeable damage to tumors when X-ray activated
- Able to deliver significant tumour damage when dually activated (X-ray followed by NIR laser) in the presence of transferrin
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted that Dr. Kaspler presented the latest PDC X-ray activation results to such a respected group of international researchers and clinicians at the 16th IPA World Congress. This initial research will allow Theralase the ability to successfully complete a Phase Ib GBM clinical study for this next generation PDT technology, demonstrating: a primary outcome of safety and tolerability and a secondary outcome of pharmacokinetics.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.
This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225